Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 312

1.

KRASG12C inhibition produces a driver-limited state revealing collateral dependencies.

Lou K, Steri V, Ge AY, Hwang YC, Yogodzinski CH, Shkedi AR, Choi ALM, Mitchell DC, Swaney DL, Hann B, Gordan JD, Shokat KM, Gilbert LA.

Sci Signal. 2019 May 28;12(583). pii: eaaw9450. doi: 10.1126/scisignal.aaw9450.

PMID:
31138768
2.

Phosphoregulation of the oncogenic protein regulator of cytokinesis 1 (PRC1) by the atypical CDK16/CCNY complex.

Hernández-Ortega S, Sánchez-Botet A, Quandt E, Masip N, Gasa L, Verde G, Jiménez J, Levin RS, Rutaganira FU, Burlingame AL, Wolfgeher D, Ribeiro MPC, Kron SJ, Shokat KM, Clotet J.

Exp Mol Med. 2019 Apr 16;51(4):44. doi: 10.1038/s12276-019-0242-2.

3.

A Legionella pneumophila Kinase Phosphorylates the Hsp70 Chaperone Family to Inhibit Eukaryotic Protein Synthesis.

Moss SM, Taylor IR, Ruggero D, Gestwicki JE, Shokat KM, Mukherjee S.

Cell Host Microbe. 2019 Mar 13;25(3):454-462.e6. doi: 10.1016/j.chom.2019.01.006. Epub 2019 Feb 28.

PMID:
30827827
4.

Chronic TGF-β exposure drives stabilized EMT, tumor stemness, and cancer drug resistance with vulnerability to bitopic mTOR inhibition.

Katsuno Y, Meyer DS, Zhang Z, Shokat KM, Akhurst RJ, Miyazono K, Derynck R.

Sci Signal. 2019 Feb 26;12(570). pii: eaau8544. doi: 10.1126/scisignal.aau8544.

PMID:
30808819
5.

Chemically reprogramming the phospho-transfer reaction to crosslink protein kinases to their substrates.

Wong AW, Urisman A, Burlingame AL, Shokat KM.

Protein Sci. 2019 Mar;28(3):654-662. doi: 10.1002/pro.3570. Epub 2019 Jan 31.

PMID:
30636329
6.

A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.

Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK.

Mol Cancer Ther. 2018 Dec;17(12):2702-2709. doi: 10.1158/1535-7163.MCT-17-1204. Epub 2018 Sep 25.

PMID:
30254185
7.

Type II Kinase Inhibitors Targeting Cys-Gatekeeper Kinases Display Orthogonality with Wild Type and Ala/Gly-Gatekeeper Kinases.

Ocasio CA, Warkentin AA, McIntyre PJ, Barkovich KJ, Vesely C, Spencer J, Shokat KM, Bayliss R.

ACS Chem Biol. 2018 Oct 19;13(10):2956-2965. doi: 10.1021/acschembio.8b00592. Epub 2018 Oct 9.

PMID:
30239186
8.

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9.

Chorba JS, Galvan AM, Shokat KM.

J Vis Exp. 2018 Aug 28;(138). doi: 10.3791/58265.

PMID:
30222160
9.

Chemical genetic inhibition of DEAD-box proteins using covalent complementarity.

Barkovich KJ, Moore MK, Hu Q, Shokat KM.

Nucleic Acids Res. 2018 Sep 28;46(17):8689-8699. doi: 10.1093/nar/gky706.

10.

Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer.

Donnella HJ, Webber JT, Levin RS, Camarda R, Momcilovic O, Bayani N, Shah KN, Korkola JE, Shokat KM, Goga A, Gordan JD, Bandyopadhyay S.

Nat Chem Biol. 2018 Aug;14(8):768-777. doi: 10.1038/s41589-018-0081-9. Epub 2018 Jun 25.

11.

Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.

Ksionda O, Mues M, Wandler AM, Donker L, Tenhagen M, Jun J, Ducker GS, Matlawska-Wasowska K, Shannon K, Shokat KM, Roose JP.

PLoS One. 2018 May 25;13(5):e0193849. doi: 10.1371/journal.pone.0193849. eCollection 2018.

12.

Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.

Chorba JS, Galvan AM, Shokat KM.

J Biol Chem. 2018 May 4;293(18):6692. doi: 10.1074/jbc.AAC118.003335. No abstract available.

13.

Disease-Causing Mutations in the G Protein Gαs Subvert the Roles of GDP and GTP.

Hu Q, Shokat KM.

Cell. 2018 May 17;173(5):1254-1264.e11. doi: 10.1016/j.cell.2018.03.018. Epub 2018 Apr 5.

14.

Novel K-Ras G12C Switch-II Covalent Binders Destabilize Ras and Accelerate Nucleotide Exchange.

Nnadi CI, Jenkins ML, Gentile DR, Bateman LA, Zaidman D, Balius TE, Nomura DK, Burke JE, Shokat KM, London N.

J Chem Inf Model. 2018 Feb 26;58(2):464-471. doi: 10.1021/acs.jcim.7b00399. Epub 2018 Jan 31.

15.

Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.

Chorba JS, Galvan AM, Shokat KM.

J Biol Chem. 2018 Feb 9;293(6):1875-1886. doi: 10.1074/jbc.RA117.000754. Epub 2017 Dec 19. Erratum in: J Biol Chem. 2018 May 4;293(18):6692.

16.

Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States.

Gentile DR, Rathinaswamy MK, Jenkins ML, Moss SM, Siempelkamp BD, Renslo AR, Burke JE, Shokat KM.

Cell Chem Biol. 2017 Dec 21;24(12):1455-1466.e14. doi: 10.1016/j.chembiol.2017.08.025. Epub 2017 Oct 12.

17.

Inhibition of Calcium Dependent Protein Kinase 1 (CDPK1) by Pyrazolopyrimidine Analogs Decreases Establishment and Reoccurrence of Central Nervous System Disease by Toxoplasma gondii.

Rutaganira FU, Barks J, Dhason MS, Wang Q, Lopez MS, Long S, Radke JB, Jones NG, Maddirala AR, Janetka JW, El Bakkouri M, Hui R, Shokat KM, Sibley LD.

J Med Chem. 2017 Dec 28;60(24):9976-9989. doi: 10.1021/acs.jmedchem.7b01192. Epub 2017 Oct 9.

18.

A new generation of mTORC1 inhibitor attenuates alcohol intake and reward in mice.

Morisot N, Novotny CJ, Shokat KM, Ron D.

Addict Biol. 2018 Mar;23(2):713-722. doi: 10.1111/adb.12528. Epub 2017 Jul 6.

19.

Drugging the 'undruggable' cancer targets.

Dang CV, Reddy EP, Shokat KM, Soucek L.

Nat Rev Cancer. 2017 Aug;17(8):502-508. doi: 10.1038/nrc.2017.36. Epub 2017 Jun 23. Review.

20.

Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes.

McGregor LM, Jenkins ML, Kerwin C, Burke JE, Shokat KM.

Biochemistry. 2017 Jun 27;56(25):3178-3183. doi: 10.1021/acs.biochem.7b00271. Epub 2017 Jun 16.

Supplemental Content

Loading ...
Support Center